UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 495

Sortiert nach

Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults

British journal of clinical pharmacology, 2023-09, Vol.89 (9), p.2867-2876

2023

Volltextzugriff (PDF)

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

Cancer, 2016-06, Vol.122 (12), p.1871-1879

2016

Volltextzugriff (PDF)

Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers

Clinical and translational science, 2020-07, Vol.13 (4), p.707-717

2020

Volltextzugriff (PDF)

Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis

CPT: pharmacometrics and systems pharmacology, 2023-12, Vol.12 (12), p.1897-1910

2023

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Basis for Effective Argatroban Dosing in Pediatrics

Journal of clinical pharmacology, 2011-01, Vol.51 (1), p.19-28

2011

Volltextzugriff (PDF)

The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers

International journal of pharmaceutics, 2002-03, Vol.234 (1), p.159-167

2002

Volltextzugriff (PDF)

Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants

British journal of clinical pharmacology, 2023-11, Vol.89 (11), p.3352-3363

2023

Volltextzugriff (PDF)

A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir

Clinical pharmacokinetics, 2024, Vol.63 (1), p.27-42

2024

Volltextzugriff (PDF)

Patient Centric Microsampling to Support Paxlovid Clinical Development: Bridging and Implementation

Clinical pharmacology and therapeutics, 2024-01, Vol.115 (1), p.42-51

2024

Volltextzugriff (PDF)

Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study

Thrombosis and haemostasis, 2002-05, Vol.87 (5), p.817

2002

Volltextzugriff (PDF)

A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

Clinical cancer research, 2017-05, Vol.23 (10), p.2405-2413

2017

Volltextzugriff (PDF)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight‐Based Intravenous Reslizumab Dosing

Journal of clinical pharmacology, 2020-08, Vol.60 (8), p.1039-1050

2020

Volltextzugriff (PDF)

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours

European journal of cancer (1990), 2013-06, Vol.49 (9), p.2077-2085

2013

Volltextzugriff (PDF)

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2017-03, Vol.12 (3), p.556-566

2017

Volltextzugriff (PDF)

Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study

The Lancet. Rheumatology, 2023-09, Vol.5 (9), p.e532-e541

2023

Volltextzugriff (PDF)

Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors

Journal of clinical pharmacology, 2015-10, Vol.55 (10), p.1184-1192

2015

Volltextzugriff (PDF)

Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects

Clinical pharmacology in drug development, 2021-10, Vol.10 (10), p.1166-1173

2021

Volltextzugriff (PDF)

Evaluation of the Effects of Food on the Single-Dose Pharmacokinetics of Trametinib, a First-in-Class MEK Inhibitor, in Patients with Cancer

Journal of clinical pharmacology, 2013-09, Vol.53 (9), p.946-954

2013

Volltextzugriff (PDF)

Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches

The Journal of pharmacology and experimental therapeutics, 2002-09, Vol.302 (3), p.1096

2002

Volltextzugriff (PDF)

Influence of Multidrug Resistance (MDR) Proteins at the Blood–Brain Barrier on the Transport and Brain Distribution of Enaminone Anticonvulsants

Journal of pharmaceutical sciences, 2001-10, Vol.90 (10), p.1540-1552

2001

Volltextzugriff (PDF)

Determination of endogenous glycosaminoglycans derived disaccharides in human plasma by HPLC: Validation and application in a clinical study

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2006-02, Vol.831 (1), p.156-162

2006

Volltextzugriff (PDF)

Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours

Cancer chemotherapy and pharmacology, 2016-09, Vol.78 (3), p.491-500

2016

Volltextzugriff (PDF)

Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers

Xenobiotica, 2014-04, Vol.44 (4), p.352-368

2014

Volltextzugriff (PDF)

Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors

Clinical pharmacology in drug development, 2015-07, Vol.4 (4), p.287-294

2015

Volltextzugriff (PDF)

1 – 25 von 495

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(344)
Mit Volltextzugriff
(414)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers

Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis

Pharmacokinetic and Pharmacodynamic Basis for Effective Argatroban Dosing in Pediatrics

The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers

Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants

A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir

Patient Centric Microsampling to Support Paxlovid Clinical Development: Bridging and Implementation

Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study

A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight‐Based Intravenous Reslizumab Dosing

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study

Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors

Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects

Evaluation of the Effects of Food on the Single-Dose Pharmacokinetics of Trametinib, a First-in-Class MEK Inhibitor, in Patients with Cancer

Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches

Influence of Multidrug Resistance (MDR) Proteins at the Blood–Brain Barrier on the Transport and Brain Distribution of Enaminone Anticonvulsants

Determination of endogenous glycosaminoglycans derived disaccharides in human plasma by HPLC: Validation and application in a clinical study

Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours

Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers

Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors

Suchergebnisse filtern